Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117946 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL1063199 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29349956 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29384797 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL31714182 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29358863 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL31369598 | 0.97 | MDM2 (0.53) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516252 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516240 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516235 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 423 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332299-A1 | COMPOUND TARGETING SSTR2, PREPARATION METHOD THEREFOR AND USE THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO LTD (CN) | 2025-10-30 | — | — | US | claimed |
| EP-4613758-A1 | COMPOUNDS TARGETING SSTR2, PREPARATION METHOD THEREFOR, AND USE THEREOF | Yantai Lannacheng Biotechnology Co., Ltd. (CN) | 2025-09-10 | — | — | EP | claimed |
| CN-119264216-B | Preparation method of tyrosine serine pseudo dipeptide | 成都普康唯新生物科技有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-119264216-A | Preparation method of tyrosine serine pseudo dipeptide | 成都普康唯新生物科技有限公司 | 2025-01-07 | — | — | CN | claimed |
| WO-2024120415-A1 | COMPOUNDS TARGETING SSTR2, PREPARATION METHOD THEREFOR, AND USE THEREOF | 烟台蓝纳成生物技术有限公司 | 2024-06-13 | — | — | WO | claimed |
| CN-116751139-A | Preparation method of N- (9-fluorenylmethoxycarbonyl) -O-tert-butyl-L-tyrosine | 山西诺成制药有限公司 | 2023-09-15 | — | — | CN | claimed |
| CN-116178500-A | Preparation method of leuprorelin related compound | 梯尔希（南京）药物研发有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-112159461-B | Synthesis method of cetrorelix | 开封明仁药业有限公司 | 2023-03-10 | — | — | CN | claimed |
| CN-112279890-B | Amphiphilic polypeptide, preparation method and application | 皖南医学院 | 2022-10-11 | — | — | CN | claimed |
| CN-113072620-B | PD-1 targeting peptide with analgesic activity, and synthesis method and application thereof | 南通大学 | 2022-07-05 | — | — | CN | claimed |
| CN-111318187-B | Chiral separation membrane based on covalent organic framework material, preparation and application thereof | 南开大学 | 2022-04-12 | — | — | CN | claimed |
| US-11180533-B2 | Process for the preparation of Cetrorelix acetate | BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2021-11-23 | — | — | US | claimed |
| CN-113072620-A | PD-1 targeting peptide with analgesic activity, and synthesis method and application thereof | 南通大学 | 2021-07-06 | — | — | CN | claimed |
| CN-112279890-A | Amphiphilic polypeptide, preparation method and application | 皖南医学院 | 2021-01-29 | — | — | CN | claimed |
| CN-112159461-A | Synthesis method of cetrorelix | 开封明仁药业有限公司 | 2021-01-01 | — | — | CN | claimed |
| CN-111318187-A | Chiral separation membrane based on covalent organic framework material, preparation and application thereof | 南开大学 | 2020-06-23 | — | — | CN | claimed |
| US-5767158-A | FOR BLEACHING SKIN | SHISEIDO CO., LTD. (JP) | 1998-06-16 | — | — | US | claimed |
| EP-4748847-A1 | PEPTIDE COMPLEX HAVING VEGFR -2 AGONIST ACTIVITY | Peptidream Inc (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-4737487-A | VASOACTIVE INTESTINAL PEPTIDE-ANTIULCER HYPOTENSIVE AGENT | BEECHAM GROUP P.L.C. (GB) | 1988-04-12 | — | — | US | disclosed |
| EP-0184309-A2 | Peptides selected from amino-acid residues 11 to 23 of VIP | BEECHAM GROUP PLC (GB) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332299-A1 | COMPOUND TARGETING SSTR2, PREPARATION METHOD THEREFOR AND USE THEREOF | SSTR2, SSTR5, SSTR3 | MDM4 4630/4885TP53 2881/4885MDM2 3177/4885 |
| US-11180533-B2 | Process for the preparation of Cetrorelix acetate | CYP51A1, CYP17A1, CYP11A1 | MDM4 4320/4885TP53 4824/4885MDM2 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.